RegHealth-RI PROJECT KICK-OFF MEETING 17-18 November 2014, Brussels European regions network for Health Research & Innovation (RegHealth-RI) project Joaquin Guinea, INNOVATEC RegHealth-RI Coordinator Brussels, 17 th November, 2014
HCO-14-2014--Bridging the divide in European health research and innovation http://ec.europa.eu/research/participants/portal/desktop/en/opportu nities/h2020/topics/2217-hco-14-2014.html
Regional disparities in R&D intensity , by NUTS 2 regions, 2011* (total R&D expenditure as a % of GDP ) 10 Capital region National average 8 Other NUTS regions 6 4 2 0 Finland Sweden Denmark Germany Austria Slovenia Estonia France Belgium Netherlands United Kingdom Ireland Czech Republic Portugal Luxembourg Spain Italy Hungary Lithuania Croatia Poland Malta Latvia Slovakia Greece Bulgaria Cyprus Romania Switzerland Iceland Norway Turkey Serbia *Source: Eurostat regional yearbook 2014 (http://epp.eurostat.ec.europa.eu/portal/page/portal/publications/regional_yearbook)
Regional disparities in R&D intensity , by NUTS 2 regions, 2011* (total R&D expenditure as a % of GDP ) *Source: Eurostat regional yearbook 2014 (http://epp.eurostat.ec.europa.eu/portal/page/portal/publications/regional_yearbook)
Regional disparities in competitiveness for the innovation sub-index, by NUTS 2 regions, 2013 (1) ( EU-28 = 0) *Source: Eurostat regional yearbook 2014 (http://epp.eurostat.ec.europa.eu/portal/page/portal/publications/regional_yearbook)
Regional competitiveness for selected dimensions of the innovation sub-index, by NUTS 2 regions, 2013 *Source: Eurostat regional yearbook 2014 (http://epp.eurostat.ec.europa.eu/portal/page/portal/publications/regional_yearbook)
HEALTH - Scientific publications (2000-09) and Technological production (EPO patents, 2000-10) in EU Regions European Commission. (2013). Research and Innovation Performance in EU Member States and Associated Countries 2013 (http://ec.europa.eu/research/innovation-union/pdf/state-of-the- union/2012/innovation_union_progress_at_country_level_2013.pdf)
REGHEALTH-RI MAIN OBJECTIVES TO PROPOSE NEW INITIATIVES AND CONCRETE APPROACHES TO EU, NATIONAL AND REGIONAL DECISION-MAKERS: • TO REDUCE THE GAPS IN HEALTH R&I ACROSS THE EU REGIONS • TO INCREASE THE PARTICIPATION IN HORIZON2020 • TO FACILITATE SYNERGIES BETWEEN HORIZON2020 AND STRUCTURAL FUNDS
RegHealth-RI PROJECT PARTNERS • Sociedad para el Fomento de la Innovacion Tecnológica (Innovatec) - Coordinator • European Regional and Local Health Authorities (EUREGHA) • University of Trieste ADVISORY BOARD MEMBERS • Prof. Jerzy Duszynski, former Deputy Minister of Science of Poland. At present he is the head of the laboratory of Bioenergetics, Nencki Institute of Experimental Biology, Warsaw – Poland • Prof. Toivo Maimets, former Minister of Education and Research of Estonia. At present he is Prof. at the Univ. of Tartu and member of the Estonian Research Council Gov. Board – Estonia • Mrs. Illiana Paunova, Chairperson of the Association of the Research-based Pharmaceutical Manufacturers in Bulgaria and General Manager of GlaxoSmithKline Bulgaria – Bulgaria • Prof. Ana Stavljenic-Rukavina, former Minister of Health of Croatia. At present she is Dean at DIU Libertas International University, Zagreb – Croatia • Mrs. María José Muñoz Martínez, Directorate General of Community Funds, Ministry of Finance and Public Administration – Spain • Prof. Jonathan Watson, Co-Founder INTEGRATE; Special Professor of Health & Public Policy, Univ. of Nottingham; External Expert to DG REGIO; Executive Director Health ClusterNet – UK
RegHealth-RI ASSOCIATE PARTNERS • August Kirchenstein Institute of Microbiology and Virology. Riga Stradins University – Latvia • Business & Innovation Centre (BIC) of Epirus – Greece • Comissão de Coordenação e Desenvolvimento Regional (CCDR) do Algarve – Portugal • Democritus University of Thrace, Department of Molecular Biology and Genetics • Estonian HealthTech Cluster – Estonia • Estonian Research Council (Horizon 2020 National Contact Point on Health) – Estonia • Fundación Pública Andaluza Progreso y Salud – Spain • Inkubator d.o.o. Sežana – Slovenia • Innovative Pharmaceutical Industry Association (IFPA) of Lithuania – Lithuania • Intermediate Managing Authority Region of Western Greece – Greece • Marche Region. Department of Research and Innovation – Italy • Marshall Office of Lubelskie Voivodeship, Dep. of Economy and Innovation – Poland • Marshal's Office Świętokrzyskie . Office of Innovation – Poland • MidTECH. National Health Service (NHS) Innovation Hub For The West Midlands – UK • Ministry of Education, Science and Sport – Slovenia • Ministry of Education and Science, Study and Research Administration – Latvia • National Documentation Centre – Greece • North-East Regional Development Agency (ADR Nord-Est) – Romania • Nutrition, Health and Longevity (NHL) Cluster (Lille) – France • Ovidius University / Clinical Hospital of Infectious Diseases, Constanța – Romania • Research Park, Autonomous University of Barcelona – Spain • Slovak Association of Research Based Pharmaceutical Companies (SAFS) – Slovakia • South Transdanubian Regional Innovation Agency – Hungary • St. Anne's University Hospital in Brno-Int. Clinical Research Center – - Czech Republic
The European regions network for Health Research and Innovation (RegHealth-RI) WORK PLAN SUMMARY: Planned Work Packages (WPs) and Events 1 st Year 2 nd Year WP1: State of the Art of health R&I in EU regions and identification and analysis of determinants influencing its performance and progression WP2 : Creation of a NETWORKING PLATFORM and organization of three Workshops to discuss the divide in European Health R&I and possible solutions WP3 : 1 st 1 st Workshop: 3 rd Workshop: 2 nd Workshop: European “ Analysis of Health “ H ORIZON 2020: “N ew approaches R&I in less Conference: Synergies with for bridging the performing EU “ Bridging the Structural Funds regions: Present divide in health and new ways for divide in situation, possible R&I in the EU Starting date: widening the causes and European regions ” participation” 01-Nov-2014 influencing factors” health R&I ” 1 st European Conference: “ B RIDGING THE DIVIDE IN E UROPEAN HEALTH R&I ” WP4: Dissemination activities WP5: Management
RegHealth-RI EXPECTED IMPACT Planned Deliverables State of the Art of the health research and innovation (R&I) in • STATE OF THE ART REPORT less performing regions • ACADEMIC DOCUMENTS WP1 • WEBSITE Launching the REGHEALTH-RI Networking Platform • NETWORKING TOOLS WS1: ‘”Analysis of Health R&I in less performing EU regions: • WORKSHOPS REPORTS Present situation and new perspectives ’” • PRESENTATIONS WP2 WS2: “New approaches for bridging the divide in health R&I • PRESS RELEASES in the EU regions” • POLICY BRIEFS WS3 : “Horizon 2020: Synergies with Structural Funds and new ways for widening the participation” • CONFERENCE REPORT • PRESENTATIONS 1 st European Conference - ‘ Bridging the divide in European • PRESS RELEASES health R&I ’ • POLICY BRIEFS WP3 • FINAL PUBLISHABLE SUMMARY REPORT DISSEMINATION (WP4) EXPECTED IMPACT ON: POLICY AND DECISSION MAKING EU : • W IDENING PARTICIPATION National and Regional DG REGIO authorities • B RIDGING THE INNOVATION DIVIDE DG Research & Inn. • S YNERGIES BETWEEN H2020 AND Companies Sci. & Tech Universities and Health & Biotech (pharma, biotech, Parks, Incubators, e S TRUCTURAL F UNDS R&D centers clusters etc.) tc .
WP1 : STATE OF THE ART OF HEALTH RESEARCH AND INNOVATION (R&I) IN EU REGIONS AND IDENTIFICATION AND ANALYSIS OF DETERMINANTS INFLUENCING ITS PERFORMANCE AND PROGRESSION MAIN OBJECTIVES OUTPUT Health Development of • Determining the State of the Art of the Definition/Classification Indicators health Research and Innovation (R&I) REPORT: State of the Art of health Research and Innovation (R&I) in EU regions and EVIDENCE- DATA SOURCES activities in EU regions looking for key identification and analysis of determinants BASED ANALYSIS influencing its performance and R&D EXPENDITURE Descriptive Stats: factors, specific differences and progression EUROSTAT Means, Variance… HEALTH / BIOTECH common patterns which could explain Multivariate Analysis: PUBLICATIONS AND Cluster, PCA… PATENTS - (DG RES. the differences between them & INNOV.) Linear Regression EC (2013). Research Analysis and innovation • Designing and developing indicators performance in EU Member States and (qualitative and quantitative) to associated countries – Innovation Union PROCESSING progress at country measure the degree of development of level Regional the health R&I across the European RIS3 Aggregations Eye@RIS3 regions HEALTH DATA ON National INFRAESTRUCTURES, TRAINING, CLINICAL Disaggregations • To elaborate a detailed report depicting TRIALS, ETC. GOVERNMENT WEBS the current situation as well as common (MINISTRY OF HEALTH, DATA FORMATTING SCI. & RESEARCH…) • Tabulation, INSTITUTIONAL • Correction patterns, differences or factors REPOSITORIES PUBLIC REPORTS • Etc … OTHERS influencing on the health R&I across EU regions Health Delineation: Data Retrieval Search Strategies
Recommend
More recommend
